{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:51:40Z","timestamp":1790095900716,"version":"4.0.1"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T00:00:00Z","timestamp":1643328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T00:00:00Z","timestamp":1643328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s12325-022-02044-1","type":"journal-article","created":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T11:02:55Z","timestamp":1643367775000},"page":"1164-1178","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["New Emerging Treatment Options for Advanced Basal Cell Carcinoma and Squamous Cell Carcinoma"],"prefix":"10.1007","volume":"39","author":[{"given":"Alessia","family":"Villani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Potestio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Fabbrocini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Scalvenzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,28]]},"reference":[{"issue":"6","key":"2044_CR1","first-page":"339","volume":"102","author":"JM Firnhaber","year":"2020","unstructured":"Firnhaber JM. Basal cell and cutaneous squamous cell carcinomas: diagnosis and treatment. Am Fam Physician. 2020;102(6):339\u201346.","journal-title":"Am Fam Physician"},{"issue":"8","key":"2044_CR2","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1158\/1078-0432.CCR-18-1122","volume":"25","author":"P Nagarajan","year":"2019","unstructured":"Nagarajan P, Asgari MM, Green AC, et al. Keratinocyte carcinomas: current concepts and future research priorities. Clin Cancer Res. 2019;25(8):2379\u201391.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2044_CR3","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jaad.2018.03.060","volume":"80","author":"MC Cameron","year":"2019","unstructured":"Cameron MC, Lee E, Hibler BP, et al. Basal cell carcinoma: epidemiology; pathophysiology; clinical and histological subtypes; and disease associations. J Am Acad Dermatol. 2019;80(2):303\u201317. (Epub ahead of print).","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"2044_CR4","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.hoc.2018.09.004","volume":"33","author":"DP Kim","year":"2019","unstructured":"Kim DP, Kus KJB, Ruiz E. Basal cell carcinoma review. Hematol Oncol Clin N Am. 2019;33(1):13\u201324.","journal-title":"Hematol Oncol Clin N Am"},{"issue":"1","key":"2044_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.hoc.2018.08.001","volume":"33","author":"A Waldman","year":"2019","unstructured":"Waldman A, Schmults C. Cutaneous squamous cell carcinoma. Hematol Oncol Clin N Am. 2019;33(1):1\u201312.","journal-title":"Hematol Oncol Clin N Am"},{"issue":"2","key":"2044_CR6","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jaad.2017.08.059","volume":"78","author":"SKT Que","year":"2018","unstructured":"Que SKT, Zwald FO, Schmults CD. Cutaneous squamous cell carcinoma: incidence, risk factors, diagnosis, and staging. J Am Acad Dermatol. 2018;78(2):237\u201347.","journal-title":"J Am Acad Dermatol"},{"key":"2044_CR7","first-page":"359","volume":"3","author":"P Nagarajan","year":"2016","unstructured":"Nagarajan P, Ivan D. Cutaneous squamous cell carcinomas: focus on high-risk features and molecular alterations. Glob Dermatol. 2016;3:359\u201365.","journal-title":"Glob Dermatol"},{"key":"2044_CR8","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1001\/jamadermatol.2015.4994","volume":"152","author":"AK Thompson","year":"2016","unstructured":"Thompson AK, Kelley BF, Prokop LJ, Murad MH, Baum CL. Risk factors for cutaneous squamous cell carcinoma recurrence, metastasis, and disease-specific death: a systematic review and meta-analysis. JAMA Dermatol. 2016;152:419\u201328.","journal-title":"JAMA Dermatol"},{"issue":"9","key":"2044_CR9","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1111\/jdv.16268","volume":"34","author":"AJG Leus","year":"2020","unstructured":"Leus AJG, Frie M, Haisma MS, et al. Treatment of keratinocyte carcinoma in elderly patients\u2014a review of the current literature. J Eur Acad Dermatol Venereol. 2020;34(9):1932\u201343.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2044_CR10","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ejca.2019.06.003","volume":"118","author":"K Peris","year":"2019","unstructured":"Peris K, Fargnoli MC, Garbe C, et al. Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines. Eur J Cancer. 2019;118:10\u201334.","journal-title":"Eur J Cancer"},{"issue":"4","key":"2044_CR11","doi-asserted-by":"crossref","first-page":"e399","DOI":"10.3747\/co.27.6015","volume":"27","author":"J Claveau","year":"2020","unstructured":"Claveau J, Archambault J, Ernst DS, et al. Multidisciplinary management of locally advanced and metastatic cutaneous squamous cell carcinoma. Curr Oncol. 2020;27(4):e399\u2013407.","journal-title":"Curr Oncol"},{"key":"2044_CR12","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ejca.2020.01.008","volume":"128","author":"AJ Stratigos","year":"2020","unstructured":"Stratigos AJ, Garbe C, Dessinioti C, et al. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: part 2. Treatment. Eur J Cancer. 2020;128:83\u2013102.","journal-title":"Eur J Cancer"},{"issue":"12","key":"2044_CR13","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1080\/14740338.2020.1837773","volume":"19","author":"A Villani","year":"2020","unstructured":"Villani A, Cinelli E, Fabbrocini G, et al. Hedgehog inhibitors in the treatment of advanced basal cell carcinoma: risks and benefits. Expert Opin Drug Saf. 2020;19(12):1585\u201394.","journal-title":"Expert Opin Drug Saf"},{"issue":"3","key":"2044_CR14","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jaad.2017.10.007","volume":"78","author":"JYS Kim","year":"2018","unstructured":"Work Group; Invited Reviewers, Kim JYS, et al. Guidelines of care for the management of cutaneous squamous cell carcinoma. J Am Acad Dermatol. 2018;78(3):560\u201378.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"2044_CR15","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3390\/cancers8020022","volume":"8","author":"TK Rimkus","year":"2016","unstructured":"Rimkus TK, Carpenter RL, Qasem S, Chan M, Lo H-W. Targeting the sonic hedgehog signaling pathway: review of smoothened and GLI inhibitors. Cancers (Basel). 2016;8(2):22.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2044_CR16","doi-asserted-by":"crossref","first-page":"8","DOI":"10.17305\/bjbms.2018.2756","volume":"18","author":"AM Skoda","year":"2018","unstructured":"Skoda AM, Simovic D, Karin V, Kardum V, Vranic S, Serman L. The role of the Hedgehog signaling pathway in cancer: a comprehensive review. Bosn J Basic Med Sci. 2018;18(1):8\u201320.","journal-title":"Bosn J Basic Med Sci"},{"issue":"4","key":"2044_CR17","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.devcel.2016.07.026","volume":"38","author":"E Pak","year":"2016","unstructured":"Pak E, Segal RA. Hedgehog signal transduction: key players, oncogenic drivers, and cancer therapy. Dev Cell. 2016;38(4):333\u201344.","journal-title":"Dev Cell"},{"issue":"3","key":"2044_CR18","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s11523-019-00648-2","volume":"14","author":"R Gutzmer","year":"2019","unstructured":"Gutzmer R, Solomon JA. Hedgehog pathway inhibition for the treatment of basal cell carcinoma. Target Oncol. 2019;14(3):253\u201367.","journal-title":"Target Oncol"},{"key":"2044_CR19","unstructured":"European Medicines Agency. Everidge (vismodegib): summary of product characteristics. 2013. Available from: European Medicines Agency. Everidge (vismodegib): summary of product characteristics. 2013. Accessed on 18 Sep 2021."},{"issue":"8","key":"2044_CR20","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1158\/1078-0432.CCR-10-2745","volume":"17","author":"PM LoRusso","year":"2011","unstructured":"LoRusso PM, Rudin CM, Reddy JC, et al. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res. 2011;17(8):2502\u201311.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2044_CR21","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1186\/s12885-019-5568-6","volume":"19","author":"A Sekulic","year":"2019","unstructured":"Sekulic A, Migden MR, Basset-Seguin N, et al. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. BMC Cancer. 2019;19(1):366.","journal-title":"BMC Cancer"},{"issue":"3","key":"2044_CR22","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/S1470-2045(17)30072-4","volume":"18","author":"B Dr\u00e9no","year":"2017","unstructured":"Dr\u00e9no B, Kunstfeld R, Hauschild A, et al. Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial. Lancet Oncol. 2017;18(3):404\u201312.","journal-title":"Lancet Oncol"},{"key":"2044_CR23","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ejca.2017.08.022","volume":"86","author":"N Basset-S\u00e9guin","year":"2017","unstructured":"Basset-S\u00e9guin N, Hauschild A, Kunstfeld R, et al. Vismodegib in patients with advanced basal cell carcinoma: primary analysis of STEVIE, an international, open-label trial. Eur J Cancer. 2017;86:334\u201348.","journal-title":"Eur J Cancer"},{"issue":"4","key":"2044_CR24","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s13555-019-00323-4","volume":"9","author":"A Villani","year":"2019","unstructured":"Villani A, Megna M, Fabbrocini G, Cappello M, Luciano MA, Costa C, Scalvenzi M. Long-term efficacy of vismodegib after its withdrawal and patients\u2019 health-related quality of life using the Dermatology Life Quality Index (DLQI). Dermatol Ther (Heidelb). 2019;9(4):719\u201324.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2044_CR25","unstructured":"European Medicines Agency. Odomzo (sonidegib): summary of product characteristics. 2015. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/odomzo-epar-product-information_en.pdf Accessed 15 Sep 2021."},{"issue":"8","key":"2044_CR26","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1080\/14740338.2021.1921734","volume":"20","author":"A Villani","year":"2021","unstructured":"Villani A, Fabbrocini G, Costa C, et al. Expert opinion on sonidegib efficacy, safety and tolerability. Expert Opin Drug Saf. 2021;20(8):877\u201382.","journal-title":"Expert Opin Drug Saf"},{"issue":"3","key":"2044_CR27","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s13555-020-00378-8","volume":"10","author":"A Villani","year":"2020","unstructured":"Villani A, Fabbrocini G, Costa C, et al. Sonidegib: safety and efficacy in treatment of advanced basal cell carcinoma. Dermatol Ther (Heidelb). 2020;10(3):401\u201312.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"6","key":"2044_CR28","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S1470-2045(15)70100-2","volume":"16","author":"MR Migden","year":"2015","unstructured":"Migden MR, Guminski A, Gutzmer R, et al. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol. 2015;16(6):716\u201328.","journal-title":"Lancet Oncol"},{"issue":"18","key":"2044_CR29","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.2217\/fon-2016-0118","volume":"12","author":"L Chen","year":"2016","unstructured":"Chen L, Silapunt S, Migden MR. Sonidegib for the treatment of advanced basal cell carcinoma: a comprehensive review of sonidegib and the BOLT trial with 12-month update. Future Oncol. 2016;12(18):2095\u2013105.","journal-title":"Future Oncol"},{"issue":"3","key":"2044_CR30","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/jdv.14542","volume":"32","author":"JT Lear","year":"2018","unstructured":"Lear JT, Migden MR, Lewis KD, et al. Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study. J Eur Acad Dermatol Venereol. 2018;32(3):372\u201381.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"2044_CR31","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1111\/bjd.18552","volume":"182","author":"R Dummer","year":"2020","unstructured":"Dummer R, Guminksi A, Gutzmer R, et al. Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study. Br J Dermatol. 2020;182(6):1369\u201378.","journal-title":"Br J Dermatol"},{"issue":"10","key":"2044_CR32","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1158\/1078-0432.CCR-12-3654","volume":"19","author":"A Jimeno","year":"2013","unstructured":"Jimeno A, Weiss GJ, Miller WH Jr, et al. Phase I study of the Hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors. Clin Cancer Res. 2013;19(10):2766\u201374.","journal-title":"Clin Cancer Res"},{"issue":"15_Supll.","key":"2044_CR33","volume":"36","author":"EH Epstein","year":"2018","unstructured":"Epstein EH, Lear J, Saldanha G, Tang JY, Harwood C. Hedge-hog pathway inhibition by topical patidegib to reduce BCC burden in patients with basal cell nevus (Gorlin) syndrome. J Clin Oncol. 2018;36(15_Supll.): e21626-e.","journal-title":"J Clin Oncol"},{"key":"2044_CR34","unstructured":"ClinicalTrials.gov. Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patie. https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT02762084?cond=patidegib&draw=2&rank=4. Accessed 15 Sep 2021."},{"key":"2044_CR35","unstructured":"Ernst D. Patidegib gets breakthrough and orphan designation for Gorlin syndrome. 2017. https:\/\/www.empr.com\/patidegib-gets-breakthrough-and-orphan-designation-for-gorlin-syndrome\/printarticle\/708449\/. Accessed 6 Feb 2018."},{"key":"2044_CR36","unstructured":"ClinicalTrials.gov. Clinical Trial of Patidegib Gel 2%, 4%, and vehicle applied once or twice daily to decrease the GLI1 biomarker in sporadic nodular basal cell carcinomas (BCC). https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT02828111?cond=patidegib&draw=2&rank=5. Accessed 15 Sep 2021."},{"key":"2044_CR37","unstructured":"ClinicalTrials.gov. Extension Study of Patidegib Topical Gel, 2% in subjects with gorlin syndrome (basal cell nevus syndrome). https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT04308395?cond=patidegib&draw=2&rank=1. Accessed 15 Sep 2021."},{"issue":"9","key":"2044_CR38","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1158\/1078-0432.CCR-17-0723","volume":"24","author":"J Bendell","year":"2018","unstructured":"Bendell J, Andre V, Ho A, et al. Phase I study of LY2940680, a Smo antagonist, in patients with advanced cancer including treatment-na\u00efve and previously treated basal cell carcinoma. Clin Cancer Res. 2018;24(9):2082\u201391.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2044_CR39","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s10637-017-0544-y","volume":"36","author":"H Ueno","year":"2018","unstructured":"Ueno H, Kondo S, Yoshikawa S, et al. A phase I and pharmacokinetic study of taladegib, a smoothened inhibitor, in Japanese patients with advanced solid tumors. Invest New Drugs. 2018;36(4):647\u201356.","journal-title":"Invest New Drugs"},{"issue":"12","key":"2044_CR40","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1007\/s12272-017-0987-x","volume":"40","author":"G Jin","year":"2017","unstructured":"Jin G, Sivaraman A, Lee K. Development of taladegib as a sonic hedgehog signaling pathway inhibitor. Arch Pharm Res. 2017;40(12):1390\u20133.","journal-title":"Arch Pharm Res"},{"key":"2044_CR41","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000775","volume":"8","author":"D Rischin","year":"2020","unstructured":"Rischin D, Migden MR, Lim AM, Schmults CD, Khushalani NI, Hughes BGM, et al. Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing. J Immunother Cancer. 2020;8: e000775. (Epub ahead of print).","journal-title":"J Immunother Cancer"},{"key":"2044_CR42","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40425-017-0228-3","volume":"5","author":"EJ Lipson","year":"2017","unstructured":"Lipson EJ, Lilo MT, Ogurtsova A, et al. Basal cell carcinoma: PD-L1\/PD-1 checkpoint expression and tumor regression after PD-1 blockade. J Immunother Cancer. 2017;5:23 (Published 2017 Mar 21).","journal-title":"J Immunother Cancer"},{"key":"2044_CR43","doi-asserted-by":"crossref","unstructured":"Villani A, Ocampo-Garza SS, Potestio L, et al. Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma. Expert Opin Drug Saf. 2021:1\u20139. (Epub ahead of print).","DOI":"10.1080\/14740338.2022.1993819"},{"key":"2044_CR44","unstructured":"LIBTAYO, Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/libtayo-epar-product-information_en.pdf. Accessed 18 Sep 2021."},{"key":"2044_CR45","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy487.002","author":"TK Owonikoko","year":"2018","unstructured":"Owonikoko TK, Papadopoulos KP, Johnson ML. Phase I study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): longer follow-up efficacy and safety data. Ann Oncol. 2018. https:\/\/doi.org\/10.1093\/annonc\/mdy487.002.","journal-title":"Ann Oncol"},{"issue":"2","key":"2044_CR46","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S1470-2045(19)30728-4","volume":"21","author":"MR Migden","year":"2021","unstructured":"Migden MR, Khushalani NI, Chang ALS, Lewis KD, Chrysalyne D, Hernandez-aya L, et al. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. Lancet Oncol. 2021;21(2):294\u2013305. (Epub ahead of print).","journal-title":"Lancet Oncol"},{"issue":"4","key":"2044_CR47","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2217\/fon-2019-0762","volume":"16","author":"MR Migden","year":"2020","unstructured":"Migden MR, Chandra S, Rabinowits G, Chen CI, Desai J, Seluzhytsky A, et al. CASE (CemiplimAb-rwlc Survivorship and Epidemiology) study in advanced cutaneous squamous cell carcinoma. Future Oncol. 2020;16(4):11\u20139.","journal-title":"Future Oncol"},{"key":"2044_CR48","doi-asserted-by":"crossref","unstructured":"Guillaume T, Puzenat E, Popescu D, Aubin F, Nardin C. Cemiplimab\u2010rwlc in advanced cutaneous squamous cell carcinoma: a real\u2010life experience in a French dermatology department. Br J Dermatol. 2021;1. (Epub ahead of print).","DOI":"10.1111\/bjd.20569"},{"issue":"2","key":"2044_CR49","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/onco.13539","volume":"26","author":"I Tsung","year":"2021","unstructured":"Tsung I, Worden FP, Fontana RJ. A pilot study of checkpoint inhibitors in solid organ transplant recipients with metastatic cutaneous squamous cell carcinoma. Oncologist. 2021;26(2):133\u20138.","journal-title":"Oncologist"},{"issue":"6","key":"2044_CR50","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S1470-2045(21)00126-1","volume":"22","author":"AJ Stratigos","year":"2021","unstructured":"Stratigos AJ, Sekulic A, Peris K, et al. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. Lancet Oncol. 2021;22(6):848\u201357.","journal-title":"Lancet Oncol"},{"issue":"8","key":"2044_CR51","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1001\/jamadermatol.2021.2206","volume":"157","author":"K Dumann","year":"2021","unstructured":"Dumann K, Artz N, Ziemer M. Complete remission of basal cell carcinoma following treatment with cemiplimab after 2 years. JAMA Dermatol. 2021;157(8):1004\u20136.","journal-title":"JAMA Dermatol"},{"issue":"10","key":"2044_CR52","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.annonc.2021.07.008","volume":"32","author":"BGM Hughes","year":"2021","unstructured":"Hughes BGM, Munoz-Couselo E, Mortier L, et al. Pembrolizumab for locally advanced and recurrent\/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial. Ann Oncol. 2021;32(10):1276\u201385.","journal-title":"Ann Oncol"},{"issue":"2","key":"2044_CR53","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.jaad.2018.08.017","volume":"80","author":"ALS Chang","year":"2019","unstructured":"Chang ALS, Tran DC, Cannon JGD, et al. Pembrolizumab for advanced basal cell carcinoma: an investigator-initiated, proof-of-concept study. J Am Acad Dermatol. 2019;80(2):564\u20136.","journal-title":"J Am Acad Dermatol"},{"key":"2044_CR54","unstructured":"Opdivo. Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/opdivo-epar-product-information_en.pdf. Accessed 18 Sep 2021."},{"key":"2044_CR55","unstructured":"YERVOY. Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/smop\/chmp-post-authorisation-summary-positive-opinion-yervoy-ws-1278_en.pdf. Accessed 18 Sep 2021."},{"issue":"1","key":"2044_CR56","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jdcr.2015.11.007","volume":"2","author":"SV Mohan","year":"2016","unstructured":"Mohan SV, Kuo KY, Chang AL. Incidental regression of an advanced basal cell carcinoma after ipilimumab exposure for metastatic melanoma. JAAD Case Rep. 2016;2(1):13\u20135 (Published 2016 Jan 8).","journal-title":"JAAD Case Rep."},{"issue":"5","key":"2044_CR57","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.jaad.2020.03.131","volume":"83","author":"DM Barrios","year":"2020","unstructured":"Barrios DM, Do MH, Phillips GS, et al. Immune checkpoint inhibitors to treat cutaneous malignancies. J Am Acad Dermatol. 2020;83(5):1239\u201353.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"2044_CR58","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1159\/000505478","volume":"12","author":"M Oro-Ayude","year":"2020","unstructured":"Oro-Ayude M, Suh-Oh HJ, Sacrist\u00e1n-Santos V, V\u00e1zquez-Bartolom\u00e9 P, Fl\u00f3rez \u00c1. Nivolumab for metastatic cutaneous squamous cell carcinoma. Case Rep Dermatol. 2020;12(1):37\u201341 (Published 2020 Feb 12).","journal-title":"Case Rep Dermatol"},{"issue":"1","key":"2044_CR59","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1684\/ejd.2017.3209","volume":"28","author":"V Blum","year":"2018","unstructured":"Blum V, M\u00fcller B, Hofer S, et al. Nivolumab for recurrent cutaneous squamous cell carcinoma: three cases. Eur J Dermatol. 2018;28(1):78\u201381.","journal-title":"Eur J Dermatol"},{"key":"2044_CR60","unstructured":"ClinicalTrials.gov. Nivolumab alone or plus relatlimab or ipilimumab for patients with locally-advanced unresectable or metastatic basal cell carcinoma. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03521830?cond=nivolumab+basal+cell+carcinoma&draw=2&rank=1. Accessed 14 Sep 2021."},{"key":"2044_CR61","unstructured":"ClinicalTrials.gov. Nivolumab with vismodegib in patients with basal cell nevus syndrome. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03767439?cond=nivolumab+basal+cell+carcinoma&draw=2&rank=5. Accessed 14 Sep 2021."},{"key":"2044_CR62","unstructured":"ClinicalTrials.gov. Neo-adjuvant nivolumab or nivolumab with ipilimumab in advanced cutaneous squamous cell carcinoma prior to surgery (MATISSE). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04620200?cond=nivolumab+cutaneous+squamous+cell+carcinoma&draw=2&rank=1. Accessed 16 Sep 2021."},{"key":"2044_CR63","unstructured":"ClinicalTrials.gov. Nivolumab in patients with advanced cutaneous squamous cell carcinoma (CA209-9JC). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03834233?cond=nivolumab+cutaneous+squamous+cell+carcinoma&draw=2&rank=2. Accessed 15 Sep 2021."},{"key":"2044_CR64","unstructured":"ClinicalTrials.gov. Nivolumab for treatment of squamous cell carcinoma of the skin. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04204837?cond=nivolumab+cutaneous+squamous+cell+carcinoma&draw=2&rank=3. Accessed 18 Sep 2021."},{"issue":"3","key":"2044_CR65","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s13555-019-0303-4","volume":"9","author":"A Villani","year":"2019","unstructured":"Villani A, Fabbrocini G, Cappello M, et al. Real-life effectiveness of vismodegib in patients with metastatic and advanced basal cell carcinoma: characterization of adverse events and assessment of health-related quality of life using the Dermatology Life Quality Index (DLQI) Test. Dermatol Ther (Heidelb). 2019;9(3):505\u201310.","journal-title":"Dermatol Ther (Heidelb)"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02044-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-022-02044-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02044-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T12:20:44Z","timestamp":1700137244000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-022-02044-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,28]]},"references-count":65,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["2044"],"URL":"https:\/\/doi.org\/10.1007\/s12325-022-02044-1","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,28]]},"assertion":[{"value":"4 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}